CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

Cancer Cell

Volumn 26, Issue 1, 2014, Pages 136-149

  Vora, SadhnaR ^a,b   Juric, Dejan ^a,b   Kim, Nayoon ^a,b   Mino Kenudson, Mari ^a,b   Huynh, Tiffany ^b   Costa, Carlotta ^a,b   Lockerman, ElizabethL ^a,b   Pollack, SarahF ^a,b   Liu, Manway ^c   Li, Xiaoyan ^c   Lehar, Joseph ^c   Wiesmann, Marion ^c   Wartmann, Markus ^c   Chen, Yan ^c   Cao, Z Alexander ^c   Pinzon Ortiz, Maria ^c   Kim, Sunkyu ^c   Schlegel, Robert ^c   Huang, Alan ^c   Engelman, JeffreyA ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; AZD 8055; BYL 719; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; LAPATINIB; LEE 011; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MICE, SCID; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904259645     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.05.020     Document Type: Article

References (40)

1. Arima Y., Inoue Y., Shibata T., Hayashi H., Nagano O., Saya H., Taya Y. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res. 2008, 68:5104-5112.
2. Averous J., Fonseca B.D., Proud C.G. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2008, 27:1106-1113.
3. Bachman K.E., Argani P., Samuels Y., Silliman N., Ptak J., Szabo S., Konishi H., Karakas B., Blair B.G., Lin C., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3:772-775.
4. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
5. Beaver J.A., Gustin J.P., Yi K.H., Rajpurohit A., Thomas M., Gilbert S.F., Rosen D.M., Ho Park B., Lauring J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin. Cancer Res. 2013, 19:5413-5422.
6. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., Demanse D., De Buck S.S., Ru Q.C., Peters M., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J.Clin. Oncol. 2012, 30:282-290.
7. Choi Y.J., Li X., Hydbring P., Sanda T., Stefano J., Christie A.L., Signoretti S., Look A.T., Kung A.L., von Boehmer H., Sicinski P. Therequirement for cyclin D function in tumor maintenance. Cancer Cell 2012, 22:438-451.
8. Elkabets M., Vora S., Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos A.B., Rodon J., Ibrahim Y.H., et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 2013, 5:96ra99.
9. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
10. García-Martínez J.M., Alessi D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 2008, 416:375-385.
11. Gazzeri S., Gouyer V., Vour'ch C., Brambilla C., Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 1998, 16:497-504.
12. Gouyer V., Gazzéri S., Bolon I., Drevet C., Brambilla C., Brambilla E. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am. J. Respir. Cell Mol. Biol. 1998, 18:188-196.
13. Grewe M., Gansauge F., Schmid R.M., Adler G., Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999, 59:3581-3587.
14. Hanker A.B., Pfefferle A.D., Balko J.M., Kuba M.G., Young C.D., Sánchez V., Sutton C.R., Cheng H., Perou C.M., Zhao J.J., et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 2013, 110:14372-14377.
15. Ilic N., Utermark T., Widlund H.R., Roberts T.M. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. USA 2011, 108:E699-E708.
16. Jamieson S., Flanagan J.U., Kolekar S., Buchanan C., Kendall J.D., Lee W.J., Rewcastle G.W., Denny W.A., Singh R., Dickson J., et al. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem. J. 2011, 438:53-62.
17. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications fordevelopment, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17:615-675.
18. Lehár J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short G.F., Staunton J.E., Jin X., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27:659-666.
19. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., Yang J., Semaan D.J., Chen C., Fox E.A., et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 2011, 17:1116-1120.
20. Liu N., Rowley B.R., Bull C.O., Schneider C., Haegebarth A., Schatz C.A., Fracasso P.R., Wilkie D.P., Hentemann M., Wilhelm S.M., et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α andp110δ activities in tumor cell lines and xenograft models. Mol. Cancer Ther. 2013, 12:2319-2330.
21. Ma B.B., Lui V.W., Hui C.W., Lau C.P., Wong C.H., Hui E.P., Ng M.H., Cheng S.H., Tsao S.W., Tsang C.M., et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 2014, 343:24-32.
22. Mahadevan D., Chiorean E.G., Harris W.B., Von Hoff D.D., Stejskal-Barnett A., Qi W., Anthony S.P., Younger A.E., Rensvold D.M., Cordova F., et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2012, 48:3319-3327.
23. Maira S.M. PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235. Mol. Cancer Ther. 2011, 10:2016.
24. Markman B., Tabernero J., Krop I., Shapiro G.I., Siu L., Chen L.C., Mita M., Melendez Cuero M., Stutvoet S., Birle D., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 2012, 23:2399-2408.
25. Miller T.W., Hennessy B.T., González-Angulo A.M., Fox E.M., Mills G.B., Chen H., Higham C., García-Echeverría C., Shyr Y., Arteaga C.L. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J.Clin. Invest. 2010, 120:2406-2413.
26. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
27. Myklebust M.P., Li Z., Tran T.H., Rui H., Knudsen E.S., Elsaleh H., Fluge Ø., Vonen B., Myrvold H.E., Leh S., et al. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br. J. Cancer 2012, 107:1684-1691.
28. Nakamura Y., Felizola S.J., Kurotaki Y., Fujishima F., McNamara K.M., Suzuki T., Arai Y., Sasano H. Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer. Prostate 2013, 73:590-595.
29. Nielsen G.P., Burns K.L., Rosenberg A.E., Louis D.N. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am. J. Pathol. 1998, 153:159-163.
30. O'Brien C., Wallin J.J., Sampath D., GuhaThakurta D., Savage H., Punnoose E.A., Guan J., Berry L., Prior W.W., Amler L.C., et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 2010, 16:3670-3683.
31. Petrovic V., Malin D., Cryns V.L. αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation. Breast Cancer Res. Treat. 2013, 138:415-425.
32. Sage J., Miller A.L., Pérez-Mancera P.A., Wysocki J.M., Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003, 424:223-228.
33. Serra V., Eichhorn P.J., García-García C., Ibrahim Y.H., Prudkin L., Sánchez G., Rodríguez O., Antón P., Parra J.L., Marlow S., et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J.Clin. Invest. 2013, 123:2551-2563.
34. Takuwa N., Fukui Y., Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell. Biol. 1999, 19:1346-1358.
35. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., Hennessy B.T., Tseng H., Pochanard P., Kim S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
36. Wang L.E., Ma H., Hale K.S., Yin M., Meyer L.A., Liu H., Li J., Lu K.H., Hennessy B.T., Li X., et al. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J.Cancer Res. Clin. Oncol. 2012, 138:377-385.
37. Wong C.H., Loong H.H., Hui C.W., Lau C.P., Hui E.P., Ma B.B., Chan A.T. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest. New Drugs 2013, 31:1399-1408.
38. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
39. Yuan J., Mehta P.P., Yin M.J., Sun S., Zou A., Chen J., Rafidi K., Feng Z., Nickel J., Engebretsen J., et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol. Cancer Ther. 2011, 10:2189-2199.
40. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.